Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Detoxified endotoxin immunogenic compositions and uses thereof
US9616116B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9616116-B2 |
| Application number | US-201514636951-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2015 |
| Priority date | Oct 24, 2005 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of Escherichia coli non-covalently complexed with group B meningococcal outermembrane protein. Also provided are methods for preventing an infection caused by a Gram-negative bacteria in an individual via administering the immunogenic compositions to the individual.
First claim
Opening claim text (preview).
What is claimed is: 1. An immunogenic composition, consisting of: a detoxified E. coli J5 core lipopolysaccharide of the Rc chemotype, non-covalently complexed with group B meningococcal outer membrane protein; and CpG 7909. 2. A method of actively immunizing an individual against infection by a heterologous Gram negative bacterium comprising administering to the individual an immunologically effective amount of the immunogenic composition of claim 1 . 3. The method of claim 2 , wherein the immunogenic composition is administered subcutaneously, intramuscularly, or intranasally. 4. The method of claim 2 , wherein the detoxified E. coli J5 core lipopolysaccharide non-covalently complexed with the group B meningococcal outer membrane protein is present in the immunogenic composition in a concentration of 5 to 50 micrograms and the CpG 7909 is present in the immunogenic composition in a concentration of 250 to 500 micrograms. 5. The method of claim 2 , wherein the immunogenic composition elicits anti-J5 core lipopolysaccharide antibodies in the individual that bind to the heterologous Gram negative bacterium.
Assignees
Inventors
Classifications
raising an immune response against a target which is not the antigen used for immunisation · CPC title
- A61K39/0258Primary
Escherichia · CPC title
CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title
Multivalent vaccine · CPC title
Polysaccharides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9616116B2 cover?
- The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of Escherichia coli non-covalently complexed with group B meningococcal outermembrane protein. Also provided are methods for preventing an infection caused by a Gram-negative bacteria in an individual via ad…
- Who is the assignee on this patent?
- Cross Alan S, Bhattacharjee Apurba K, Zollinger Wendell D, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0258. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).